Evaluation of MicroScan Neg Combo Panel Type 44 for detecting extended spectrum b-lactamases in Enterobacteriaceae
Abstract number: P1172
Kim M.N., Sung H., Song A.J., Lee S.J.
Objectives: Accurate and rapid detection of extended spectrum b-lactamases (ESBLs) is important to guide proper patient antimicrobial therapy. The new MicroScan panel, Neg Combo Type 44 (Dade Behring, Sacramento, Calif., USA), has been developed for confirmation of ESBL-producing Enterobacteriaceae using the wells containing ceftazidime/clavulanic acid and cefotaxime/clavulanic acid. We evaluated the performance of Type 44 panel for confirmation of ESBLs.
Methods: In September 2007, 106 Escherichia coli, 81 Klebsiella pneumoniae, 11 K. oxytoca, and 8 Proteus mirabilis isolated from clinical specimens were tested with Type 44 panel. All isolates were tested with the disk approximation test (DAT) and CLSI phenotypic ESBL confirmation test (CLSI). The cefotetan-non-susceptible isolates were tested with cefotaxime and cefotaxime/clavulanate disk containing boronic acid for detection of plasmid-mediated AmpC b-lactamases (AmpC).
Result: Forty-four (21.4%) of 206 isolates were confirmed as ESBL-producers by DAT and/or CLSI including 27 E. coli, 14 K. pneumoniae, 2 K. oxytoca, and 1 P. mirabilis. Thirty-eight isolates flagged as "Confirmed ESBL" were all confirmed as ESBL-producers. Fourteen K. pneumoniae isolates flagged as "Possible ESBL, unable to interpret confirm test" were all confirmed as AmpC-producers. Of which, 6 (2.9%) were ESBL-producing as well as AmpC. All ESBL-producers were positively screened and ESBL-producers without AmpC were all confirmed by Type 44.
Conclusion: Type 44 warrants to be a reliable panel for detection of ESBLs in Enterobacteriaceae. The isolates that flagged as "Possible ESBL, unable to interpret confirm test" requires the confirmation for presence of AmpC.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|